Capricor receives FDA clarity on Deramiocel approval path for DMD Sep 25, 2025 07:15AM
Capricor Therapeutics Provides Regulatory Update on Deramiocel Program for Duchenne Muscular Dystrophy Following Type A Meeting Sep 25, 2025 07:15AM
Capricor responds to FDA posting of Deramiocel rejection letter Sep 9, 2025 09:23AM
Capricor Therapeutics Responds to FDA Posting of Complete Response Letter (CRL) for Deramiocel Sep 9, 2025 09:20AM
Capricor begins dosing patients in Phase 1 trial of exosome vaccine Aug 18, 2025 09:00AM
View Older Stories

Aug 18, 2025 09:00AM Capricor Therapeutics Announces First Subjects Dosed in Phase 1 Clinical Trial of Novel Exosome-Based Vaccine
Aug 11, 2025 04:05PM Capricor Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Aug 8, 2025 08:30AM Capricor schedules FDA meeting on Deramiocel regulatory path
Aug 8, 2025 08:30AM Capricor Therapeutics Announces Type A Meeting Scheduled with U.S. FDA
Aug 6, 2025 09:00AM Capricor Therapeutics to Present Second Quarter 2025 Financial Results and Recent Corporate Update on August 13
Jul 28, 2025 09:00AM Capricor Therapeutics and Parent Project Muscular Dystrophy to Host Webinar to Review Latest Developments in the Deramiocel Program for the Treatment of Duchenne Muscular Dystrophy
Jul 11, 2025 06:30AM Capricor receives FDA rejection for Duchenne muscular dystrophy treatment
Jul 11, 2025 06:30AM Capricor Therapeutics Provides Regulatory Update on Deramiocel BLA for Duchenne Muscular Dystrophy
Jun 24, 2025 09:01AM Capricor Therapeutics (CAPR) Provides Regulatory Update on Deramiocel BLA for Duchenne Muscular Dystrophy
Jun 24, 2025 09:00AM Capricor Therapeutics Provides Regulatory Update on Deramiocel BLA for Duchenne Muscular Dystrophy
Jun 20, 2025 09:25AM Capricor Therapeutics (CAPR) Announces Positive 4-Year Data from HOPE-2 Open-Label Extension Study of Deramiocel in Duchenne Muscular Dystrophy
Jun 20, 2025 09:25AM Capricor Therapeutics Announces Positive 4-Year Data from HOPE-2 Open-Label Extension Study of Deramiocel in Duchenne Muscular Dystrophy
Jun 17, 2025 09:01AM Capricor Therapeutics (CAPR) Announces Orphan Drug Designation for Becker Muscular Dystrophy and Regulatory Progress for Duchenne Muscular Dystrophy Program
Jun 17, 2025 09:00AM Capricor Therapeutics Announces Orphan Drug Designation for Becker Muscular Dystrophy and Regulatory Progress for Duchenne Muscular Dystrophy Program
Jun 11, 2025 09:25AM Capricor Therapeutics (CAPR) Announces Key Regulatory Updates for its Duchenne Muscular Dystrophy Program
Jun 11, 2025 09:25AM Capricor Therapeutics Announces Key Regulatory Updates for its Duchenne Muscular Dystrophy Program
May 13, 2025 04:05PM Capricor Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
May 13, 2025 09:01AM Capricor Therapeutics (CAPR) Appoints Michael Binks as Chief Medical Officer
May 13, 2025 09:00AM Capricor Therapeutics Appoints Michael Binks, M.D. as Chief Medical Officer
May 6, 2025 09:15AM Capricor Therapeutics to Present First Quarter 2025 Financial Results and Recent Corporate Update on May 13
May 5, 2025 08:06AM Capricor Therapeutics (CAPR) Announces Completion of Mid-Cycle Review Meeting with FDA on Deramiocel for the Treatment of Duchenne Muscular Dystrophy Cardiomyopathy
May 5, 2025 08:00AM Capricor Therapeutics Announces Completion of Mid-Cycle Review Meeting with FDA on Deramiocel for the Treatment of Duchenne Muscular Dystrophy Cardiomyopathy
Apr 1, 2025 09:00AM Capricor Therapeutics to Present at the 2025 Piper Sandler Virtual Cardio Day
Mar 19, 2025 04:05PM Capricor Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
Mar 17, 2025 09:25AM Capricor Therapeutics (CAPR) Announces Positive Data Demonstrating Long-Term Efficacy of Deramiocel
Mar 17, 2025 09:25AM Capricor Therapeutics Announces Positive Data Demonstrating Long-Term Efficacy of Deramiocel for the Treatment of Duchenne Muscular Dystrophy
Mar 11, 2025 09:00AM Capricor Therapeutics to Present Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Update on March 19
Mar 7, 2025 09:25AM Capricor Therapeutics to Present at Leerink’s Global Healthcare Conference 2025
Mar 4, 2025 07:02AM Capricor Therapeutics (CAPR) Announces FDA Acceptance and Priority Review of its Biologics License Application for Deramiocel to Treat Duchenne Muscular Dystrophy
Mar 4, 2025 07:00AM Capricor Therapeutics Announces FDA Acceptance and Priority Review of its Biologics License Application for Deramiocel to Treat Duchenne Muscular Dystrophy
Feb 10, 2025 09:00AM Capricor Therapeutics to Participate in Upcoming Investor Conferences
Jan 2, 2025 09:15AM Capricor Therapeutics (CAPR) Completes Submission of Biologics License Application to the U.S. FDA for Deramiocel
Jan 2, 2025 09:15AM Capricor Therapeutics Completes Submission of Biologics License Application to the U.S. FDA for Deramiocel for the Treatment of Duchenne Muscular Dystrophy
Dec 2, 2024 04:15PM Capricor Therapeutics to Present at Upcoming Investor Conferences
Nov 20, 2024 09:02AM Capricor Therapeutics (CAPR) Granted Orphan Drug and ATMP Status for Deramiocel by European Medicines Agency
Nov 20, 2024 09:00AM Capricor Therapeutics Granted Orphan Drug and ATMP Status for Deramiocel by European Medicines Agency
Nov 13, 2024 04:01PM Capricor Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Nov 12, 2024 09:00AM Capricor Therapeutics to Present Exosome Platform Updates at 2024 American Association of Extracellular Vesicles Annual Meeting
Nov 5, 2024 09:00AM Capricor Therapeutics to Present Third Quarter 2024 Financial Results and Recent Corporate Update on November 13
Oct 18, 2024 04:01PM Capricor Therapeutics Announces Closing of Underwritten Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
Oct 17, 2024 06:00AM Capricor Therapeutics (CAPR) Prices $75M Share Offering at $17/sh
Oct 17, 2024 06:00AM Capricor Therapeutics Announces Pricing of Approximately $75 Million Public Offering of Common Stock
Oct 16, 2024 04:18PM Capricor Therapeutics (CAPR) Announces Proposed Public Offering of Common Stock
Oct 16, 2024 04:17PM Capricor Therapeutics Announces Proposed Public Offering of Common Stock
Oct 11, 2024 09:15AM Capricor Therapeutics (CAPR) Announces Positive Long-Term Data from HOPE-2 OLE Study in Duchenne Muscular Dystrophy at 2024 World Muscle Society Congress
Oct 11, 2024 09:15AM Capricor Therapeutics Announces Positive Long-Term Data from HOPE-2 OLE Study in Duchenne Muscular Dystrophy at 2024 World Muscle Society Congress
Oct 9, 2024 09:15AM Capricor Therapeutics (CAPR) Announces Initiation of Rolling Submission of Biologics License Application (BLA) with U.S. FDA for Deramiocel for the Treatment of DMD
Oct 9, 2024 09:15AM Capricor Therapeutics Announces Initiation of Rolling Submission of Biologics License Application (BLA) with U.S. FDA for Deramiocel for the Treatment of Duchenne Muscular Dystrophy
Oct 4, 2024 09:15AM Capricor Therapeutics to Present Long-Term Data from HOPE-2 Open Label Extension Study at 2024 World Muscle Society Congress
Sep 24, 2024 08:01AM Capricor Therapeutics (CAPR) Announces Intent to File Biologics License Application for Full Approval of Deramiocel for the Treatment of Duchenne Muscular Dystrophy Cardiomyopathy
View Older Stories